Overview
Deepcell provides high-content single-cell analysis and sorting using the REM-I platform, which combines label-free imaging, microfluidics, and AI analytics. Cells flow through microfluidic channels, label-free images are captured, and deep learning analyzes morphology and other signals to classify and quantify cells; the platform can gently sort cells based on these readouts and deliver rich data. It differentiates itself by unifying microfluidics, AI-driven image interpretation, and high-dimensional outputs in one system aimed at detailed phenotyping without chemical labels. Its goal is to help researchers and pharma teams obtain precise cellular phenotyping and sorting to accelerate discovery and drug development with data-rich, single-cell insights.
Work here?Claim your company
Simplify's take
What believers are saying
- Deepcell raised $14.9 million in August 2026, extending runway and product development.
- April 2026 REM-I OnSite broadens sales into regulated pharma and international deployments.
- January 2026 publications and 2026 blog studies show REM-I driving diagnostic and therapeutic workflows.
What critics are saying
- Simplify Jobs says headcount fell from 115 in 2023 to 38 by March 2026.
- Commercialization depends on converting collaborations into repeatable instrument sales before cash tightens.
- If Gilead or big pharma internalize morphology models, Deepcell loses its core platform advantage.
What makes Deepcell unique
- REM-I links label-free imaging, AI, and gentle sorting in one workflow.
- Deepcell’s August 2026 Gilead partnership validates CHO morphology modeling for bioprocessing.
- REM-I OnSite keeps analysis air-gapped for GxP and sovereignty-sensitive customers.
Help us improve and share your feedback! Did you find this helpful?
